Clinical Trial Update: Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating gemcitabine and bendamustine in relapsed or refractory Hodgkin lymphoma; completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Beth Christian | Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-11-19